• Baccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., Hochhaus, A., Horowitz, M., Hughes, T., Kantarjian, H., Larson, R., Radich, J., Simonsson, B., Silver, R.T., Goldman, J & Hehmann, R; European LeukemiaNet. (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27, 60416051.
  • Cortes, J., O'Brien, S. & Kantarjian, H. (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood, 104, 22042205.
  • Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C., Kimura, S., Ottmann, O.G., Druker, B.J., Villunger, A., Roberts, A.W. & Strasser, A. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceeding of the National Academy of Science of the United States of America, 103, 1490714912.
  • Mahon, F.X., Réa, D., Guilhot, J., Guilhot, F., Huguet, F., Nicolini, F., Legros, L., Charbonnier, A., Guerci, A., Varet, B., Etienne, G., Reiffers, J. & Rousselot, P; Intergroupe Français des Leucémies Myéloïdes Croniques. (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib (STIM) trial. Lancet Oncology, 11, 10291035.
  • Ng, K.P., Hillmer, A.M., Chuah, C.T.H., Juan, W.C., Ko, T.K., Teo, A.S., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W., Allen, Jr, J.C. ., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowba, y B., Chang, C.T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., See, t J.E., Ang, M.K., Chau, N.M., Ng, Q.S., Tan, D.S., Soda, M., Isobe, K., Nöthen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.T., Ruan, Y. & Ong, S.T. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nature Medicine, 18, 521528.
  • Ohyashiki, K., Katagiri, S., Tauchi, T., Ohyashiki, J.H., Maeda, Y., Matsumura, I. & Kyo, T. (2012) Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib. British Journal of Haematology, 157, 254256.
  • Ross, D.M., Branford, S., Seymour, J.F., Schearer, A.P., Arthur, C., Bartley, P.A., Slader, C., Field, C., Dang, P., Filshie, R.J., Mills, A.K., Grigg, A.P., Melo, J.V. & Hughes, T.P. (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia, 24, 17191724.
  • Takahashi, N., Kyo, T., Maeda, Y., Sugihara, T., Usuki, K., Kawaguchi, T., Usui, N., Okamoto, S., Ohe, Y., Ohtake, S., Kitamura, K., Yamamoto, M., Teshima, H., Motoji, T., Tamaki, T., Sawada, K. & Ohyashiki, K. (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica, 97, 903906.